Literature DB >> 11455851

Combination therapies for systemic sclerosis.

C P Denton1, C M Black.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11455851     DOI： 10.1007/s002810100058

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  62 in total

1.  Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

Authors:  J R Seibold; J H Korn; R Simms; P J Clements; L W Moreland; M D Mayes; D E Furst; N Rothfield; V Steen; M Weisman; D Collier; F M Wigley; P A Merkel; M E Csuka; V Hsu; S Rocco; M Erikson; J Hannigan; W S Harkonen; M E Sanders
Journal:  Ann Intern Med       Date:  2000-06-06       Impact factor: 25.391

2.  Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group.

Authors:  W Stevens; R Vancheeswaran; C M Black
Journal:  Br J Rheumatol       Date:  1992-10

3.  Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma.

Authors:  A Gough; D Andrews; P A Bacon; P Emery
Journal:  Br J Rheumatol       Date:  1995-10

4.  Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.

Authors:  E N Unemori; L B Pickford; A L Salles; C E Piercy; B H Grove; M E Erikson; E P Amento
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

6.  A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].

Authors:  S A Jimenez; S H Sigal
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

7.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

8.  Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.

Authors:  C M Black; L Halkier-Sørensen; J J Belch; S Ullman; R Madhok; A J Smit; J D Banga; H R Watson
Journal:  Br J Rheumatol       Date:  1998-09

9.  Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.

Authors:  C P Denton; M C Bickerstaff; X Shiwen; M T Carulli; D O Haskard; R M Dubois; C M Black
Journal:  Br J Rheumatol       Date:  1995-11

10.  The watermelon stomach: long-term outcome in patients treated with Nd:YAG laser therapy.

Authors:  S M Liberski; T J McGarrity; R J Hartle; V Varano; D Reynolds
Journal:  Gastrointest Endosc       Date:  1994 Sep-Oct       Impact factor: 9.427
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.